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Introduction
Tissue remodeling and fibrosis are major features of  fibrotic diseases, including those affecting the lung, 
such as idiopathic pulmonary fibrosis (IPF) (1, 2). Fibrosis results from the excessive tissue deposition 
of  extracellular matrix (ECM) proteins produced predominantly from myofibroblasts, which leads to 
increased collagen deposition in tissues (3). Multiple ECM proteins are involved in fibrosis, including col-
lagens, fibronectin (Fn), periostin (Postn), and tenascin-C (Tnc) (3–5). The mechanisms that drive fibrosis 
involve TGF-β–mediated pathways (6), but how these are induced remains incompletely understood.
IPF is a chronic, progressive, and lethal interstitial fibrotic lung disease that occurs primarily in older adults 
(7). Its prognosis is poor, with an average survival of 2–3 years after diagnosis, shorter than most cancers (7, 8). 
IPF is characterized by dyspnea, dry cough, and progressive airway and lung tissue remodeling (9). Patients with 
IPF have increased collagen deposition around the small airways (10) and interstitial and airspace fibrosis of  
the lung parenchyma (11). This leads to reduced lung function, including a decline in forced vital capacity that 
accompanies disease progression (12). The cause of IPF is unknown; however, cigarette smoke, environmental 
insults, and genetic predisposition are primary etiological factors (13, 14), and TGF-β–mediated pathways and 
downstream Smad signal transducers are well known to be involved (6). Current therapies directly target the 
tissue remodeling in IPF but have limited efficacy. Nintedanib targets multiple receptors and tyrosine kinases 
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and slows disease progression in patients with IPF (15). Pirfenidone, an antifibrotic drug, downregulates the pro-
duction of TGF-β and suppresses the progression of pulmonary fibrosis (6). Both drugs delay the impairment of  
lung function and improve the survival rate of patients with IPF (6, 15). However, these treatments are not cures, 
often have debilitating side effects, and delay rather than inhibit or reverse pulmonary remodeling.
Fibulin-1 (Fbln1), a secreted glycoprotein, is an important matricellular ECM protein (16). It facil-
itates the stabilization and binding of  other ECM proteins, such as Fn, Postn, Tnc, and versican during 
collagen deposition (1). There are 4 Fbln1 variants (Fbln1a, -b, -c, and -d) in humans that differ in their 
C-terminal sequences, but only Fbln1c and -d occur in mice (17). Fbln1c is the variant that is associated 
with respiratory diseases in humans and mice (1, 18). We previously showed that Fbln1 protein levels are 
increased in serum/plasma and lung tissue from patients with IPF (18); however, the level of  the Fbln1c 
variant was not assessed. We also showed that a Fbln1c peptide increases the proliferation of  lung fibro-
blasts from patients with IPF (19) and that Fbln1c-deficient (Fbln1c–/–) mice are protected against bleomy-
cin-induced small airway remodeling (1). We also showed similar roles for Fbln1c in fibrosis in chronic 
obstructive pulmonary disease (COPD) and asthma (1, 20). However, the roles of  Fbln1c in pulmonary 
fibrosis and the mechanisms involved remain unknown.
In this study, we show that Fbln1c levels are increased in the lung tissues of  patients with IPF and 
demonstrate that Fbln1c is essential for the development of  an experimental model of  pulmonary fibrosis. 
Inhibition of  Fbln1c in mice protects them from developing airway and lung remodeling/fibrosis through 
the attenuation of  the TGF-β signaling pathway and myofibroblast generation. We identify a potentially 
novel mechanism that involves Fbln1c binding to latent TGF-β–binding protein 1 (LTBP1) to activate the 
TGF-β signaling pathway to induce fibrosis. These data increase fundamental understanding of  develop-
ment of  fibrosis, and Fbln1c may drive TGF-β activation and signaling and be a potential upstream thera-
peutic target in IPF and other fibrotic diseases.
Results
Fbln1 levels are increased in the lung tissues of  patients with IPF. To understand the role of  Fbln1c in fibrosis, we 
used IPF, one of  severe fibrotic diseases (9), as an example. Lung tissues were obtained from patients with 
IPF and controls with normal lungs (Table 1). Fbln1c protein levels, measured by immunohistochemistry, 
were significantly increased specifically in fibrotic areas of  the lungs from patients with IPF but not in non-
fibrotic areas or in the lungs from controls (Figure 1A).
Fbln1c is increased around small airways and in lungs in experimental bleomycin-induced pulmonary fibrosis. To 
determine the role of  Fbln1c in pulmonary fibrosis, a previously described experimental model of  bleo-
mycin-induced lung fibrosis was used (21–23). One dose of  bleomycin was administered (0.05 U, intra-
nasally), and collagen deposition around the small airways and in lungs was assessed after 7, 14, 21, and 
Table 1. Human subject history
Donor Sex Age Diagnosis Smoking history
Non-IPF control 1 Male 30 Resection for thoracic malignancy None
Non-IPF control 2 Female 62 Resection for thoracic malignancy Ex-smoker
Non-IPF control 3 Male 47 MVA None
Non-IPF control 4 Male 60 Emphysema Ex-smoker
Non-IPF control 5 Female 62 Resection for thoracic malignancy Ex-smoker
Non-IPF control 6 Male 19 MVA None
Non-IPF control 7 Male 52 Healthy — hemorrhage None
Non-IPF control 8 Female 62 Emphysema None
IPF 1 Female IPF None
IPF 2 Male 52 IPF None
IPF 3 Male 57 IPF Ex-smoker
IPF 4 Male 55 IPF Ex-smoker
IPF 5 Female 58 IPF None
IPF 6 Male 58 IPF Ex-smoker
IPF 7 Male 58 IPF None
All patients with IPF had end-stage disease and had lung transplantation. MVA, motor vehicle accident.
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28 days. Bleomycin challenge induced significant deposition of  collagen around the small airways after 
21 days, which increased further after 28 days, compared with sham-challenged controls (Figure 1B and 
Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/
jci.insight.124529DS1). Concomitant with this, there were significant increases in the levels of  total lung 
hydroxyproline, a surrogate marker for elevated total collagen levels, following bleomycin challenge, in 
whole lung tissues after 28 days (Supplemental Figure 1).
We then measured Fbln1 protein levels around the airways and in whole lung tissues over the 28-day 
time course after bleomycin challenge using immunohistochemistry. Fbln1 deposition around the small 
airways was significantly increased from 14 days, compared with sham-challenged controls (Figure 1B and 
Supplemental Figure 2). Fbln1 protein levels in whole lung tissues assessed using immunoblotting were 
also significantly increased following bleomycin exposure after 21 and 28 days (Figure 1C).
Lung fibrosis was maximally increased around the airways and in the lungs after 28 days; thus, we 
measured Fbln1c-specific protein levels in mouse lung sections at this time point. Deposition of  Fbln1c was 
Figure 1. Fbln1c is increased in patients with IPF and bleomycin-induced experimental pulmonary fibrosis. (A) Fbln1c deposition in lung sections from 
the nonfibrotic area and fibrotic area in patients with IPF and from healthy lung controls stained using immunohistochemistry (left); scale bar: 200 μm. 
Fbln1c-stained areas were quantified with normalization to the total area (right, n = 7–8). A single bleomycin challenge was used to induce pulmonary 
fibrosis in WT and Fbln1c–/– mice. Controls were challenged with PBS. #P < 0.05, compared to nonfibrotic IPF. (B) Stained areas of total Fbln1 were quanti-
fied around small airways with normalization to the perimeter of the basement membrane (Pbm) (n = 6–8). (C) Fbln1 protein levels were assessed using 
immunoblot of whole lung tissues (left), and fold change of densitometry was normalized to β-actin and quantified (right, n = 8). (D) Twenty-eight days 
after bleomycin or PBS challenge, lung sections were assessed for protein of the 1c isoform, Fbln1c, around small airways using immunofluorescence (top); 
scale bar: 50 μm. (Insets show expanded images of indicated regions; scale bar: 15 μm.) Fbln1c-stained areas around airways were quantified with normal-
ization to the Pbm (bottom, n = 8). (E) Fbln1c protein area in parenchyma was determined using immunofluorescence (left); scale bar: 50 μm. Fbln1c-
stained areas were quantified with normalization to total area (right, n = 8). (F) Fbln1c protein levels were assessed in whole lungs using immunoblot 
(top), and fold change of densitometry was quantified with normalization to β-actin (bottom, n = 8). Statistical differences were determined with 2-tailed 
Student’s t test. *P < 0.05, **P < 0.01, and ***P < 0.001 compared with human healthy lung controls or PBS-challenged mouse controls.
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significantly increased around the small airways (Figure 1D) and in the parenchyma (Figure 1E) 28 days 
after bleomycin challenge, and the Fbln1c protein levels were also increased in whole lung tissue (Figure 
1F). The increased levels of  Fbln1 and Fbln1c in mice treated with 28 days of  bleomycin challenge are 
similar, indicating that Fbln1c plays key roles in lung fibrosis compared with Fbln1d.
Genetic deletion of  Fbln1c protects against experimental bleomycin-induced pulmonary fibrosis. The 28-day time 
point after bleomycin treatment was also used to assess the effect of  Fbln1c deficiency. Deletion of  all Fbln1 
isoforms in mice is embryonically lethal; thus, Fbln1c–/– mice were created and used (1). Fbln1c mRNA lev-
els were significantly increased in wild-type (WT) mouse lungs 28 days after bleomycin challenge but were 
undetectable in Fbln1c–/– mice (Figure 2A). However, Fbln1d mRNA levels in WT and Fbln1c–/– mice were 
not altered (Figure 2B). The absence of  Fbln1c completely inhibited the development of  bleomycin-induced 
collagen deposition around the small airways compared with WT mice (Figure 2C), congruent with our 
previous findings in COPD (1). In addition, Fbln1c deficiency completely prevented increases in total and 
soluble collagen levels (Figure 2D) and in type I collagen α1 (Col1a1), the most abundant collagen in dis-
eased lungs, in whole lung tissues (Figure 2, E and F).
Second harmonic generation (SHG) microscopy has been recently used as a powerful and robust tool 
to visualize changes in collagen microstructure in tissues (24, 25). SHG emits 2-photon scattering in the 
focal volume, forward (FSHG) and backward (BSHG), and the FSHG/BSHG relationship is sensitive to the spa-
tial extent of  SHG-generated scattering to indicate the disorder of  arrangement and density of  collagen 
fibrils. The ratio of  the FSHG/BSHG area was significantly increased in WT mice 28 days after bleomycin 
challenge compared with controls (Figure 2G and Supplemental Figure 3). Again, Fbln1c–/– mice were 
protected against this increase.
The balance of  matrix metalloproteinase (MMP) and tissue inhibitor of  metalloproteinase (TIMP) reg-
ulates ECM protein production (1). Thus, we then measured the mRNA levels of  these proteins in the lungs 
from WT and Fbln1c–/– mice. Bleomycin-challenged WT mice had substantial increases in the mRNA levels 
of  Mmp1, -3, -8, -12, and -13 in lung tissues after 28 days compared with controls (Supplemental Figure 4, 
A–E). These increases were abrogated in Fbln1c–/– mice. The mRNA levels of  Timp1 were also increased in 
bleomycin-challenged WT mice but not Fbln1c–/– mice (Supplemental Figure 4F).
To determine whether protection against pathological changes in Fbln1c–/– mice prevented functional 
changes, lung function parameters were assessed in WT and Fbln1c–/– mice 28 days after bleomycin chal-
lenge. Bleomycin challenge increased tissue damping and tissue elastance and reduced lung compliance in 
WT mice, but Fbln1c–/– mice were protected against these changes (Figure 2, H–J).
Fbln1c deficiency protects against bleomycin-induced accumulation of  Fn and Tnc around the small airways and 
in whole lung tissues. Fbln1 is critical for ECM stabilization (1); thus, we next assessed the specific role of  
Fbln1c in the deposition of  ECM and remodeling around the small airways in bleomycin-induced pulmo-
nary fibrosis. Bleomycin challenge induced Fn and Tnc deposition in the basement membrane around the 
small airways after 28 days in WT mice (Figure 3, A and B). Again, Fbln1c–/– mice were protected against 
these changes. In contrast, Postn deposition was not altered in WT or Fbln1c–/– mice (Figure 3C).
We then assessed the role of  Fbln1c in ECM protein deposition in whole lung tissues. Bleomycin 
challenge substantially increased Fn and Tnc mRNA levels in WT mouse lungs, whereas Fbln1c–/– mice 
were protected (Figure 3, D and E). Postn mRNA levels in lungs were not altered in WT or Fbln1c–/– mice 
after bleomycin challenge (Figure 3F). Bleomycin challenge resulted in increased Fn protein levels in 
the lungs from WT mice compared with controls, whereas Tnc (either variant) and Postn levels were 
not altered (Figure 3G). The levels of  all of  these proteins were significantly reduced in bleomycin-chal-
lenged Fbln1c–/– mice compared with WT controls. Tnc and Postn levels were significantly reduced even 
compared with controls not treated with bleomycin. We also measured the deposition of  other ECM 
components, versican and ECM1, but found no significant differences between bleomcyin-challenged 
WT and Fbln1c–/– mice compared to controls (not shown).
Fbln1c binds with LTBP1 to activate TGF-β. To investigate the mechanisms involved in Fbln1c-reg-
ulated pulmonary fibrosis, we measured the levels of  TGF-β, its activation, and its regulation in the 
lungs of  bleomycin-challenged mice. The mRNA levels of  Tgfb were increased in the lung tissues 
of  bleomycin-challenged WT and Fbln1c–/– mice (Figure 4A). The levels of  active TGF-β1 proteins 
measured by ELISA were increased in WT mice; however, levels of  active TGF-β1 did not increase in 
Fbln1c–/– mice (Figure 4B). LTBP1 regulates TGF-β1 activation, and its levels were increased in both 
WT and Fbln1c–/– mice after bleomycin challenge, with no significant differences between them (Figure 
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4C). We then measured the downstream molecules in the TGF-β signaling pathway, Smad2, Smad3, 
and Smad4. Bleomycin challenge significantly reduced Smad3 mRNA levels (Supplemental Figure 5A) 
but increased phosphorylated Smad3 (p-Smad3) protein levels in the lungs of  WT but not Fbln1c–/– 
mice (Figure 4D). In contrast, the mRNA levels of  Smad2 and Smad4 in the lungs of  WT and Fbln1c–/– 
mice were not altered (Supplemental Figure 5, B and C).
To further assess mechanisms, we immunoprecipitated Fbln1c and identified its binding relationship 
with LTBP1. LTBP1s were detectable when immunoprecipitated with Fbln1c from naive WT mouse lung 
lysates assessed using immunoblot (Figure 4E). This did not occur in proteins from Fbln1c–/– mice. This 
confirmed that a binding interaction exists between Fbln1c and LTBP1.
Collectively these data show that the absence of  Fbln1c does not affect LTBP1 levels but that Fbln1c is 
required for the activation of  TGF-β1 and downstream Smad3 phosphorylation.
Fbln1c regulates fibroblast activation and conversion into myofibroblasts and collagen deposition. To further 
investigate the role of  Fbln1c in the mechanisms of  pathogenesis of  fibrosis, primary lung fibroblasts were 
isolated from WT and Fbln1c–/– mice and stimulated with recombinant TGF-β1 protein. As we stimulated 
fibroblasts with recombinant TGF-β1 protein, we could not distinguish between TGF-β1 protein that was 
Figure 2. Bleomycin challenge of Fbln1c–/– mice does not induce airway or lung fibrosis or impair lung function. A single bleomycin challenge was used to 
induce pulmonary fibrosis in WT and Fbln1c–/– mice that were assessed 28 days later. Controls received PBS. (A) Fbln1c and (B) Fbln1d mRNA levels in whole 
lungs determined using quantitative real-time PCR (qRT-PCR) (n = 6–8). (C) Lung sections were stained with Verhoeff-Van Gieson stain (left, scale bar: 500 
μm; insets show expanded images of indicated regions; scale bar: 50 μm) and areas of collagen around small airways quantified with normalization to the 
Pbm (right, n = 8). (D) Total collagen levels were assessed by measuring hydroxyproline (left) and soluble collagen (right) in the whole lung tissues (n = 8). 
(E) Type I collagen (Col1a1) mRNA levels were measured in whole lungs using qRT-PCR (n = 8). (F) Col1a1 protein levels were measured in whole lungs using 
immunoblot (left), and fold change was quantified with normalization to β-actin (right, n = 8). (G) Collagen fibers were detected by second harmonic gener-
ation (SHG) microscopy (left), and fiber areas were calculated by forward (FSHG)/backward (BSHG) SHG ratios (right, n = 4–6; scale bar: 100 μm). Lung function 
in terms of (H) tissue damping, (I) tissue elastance, and (J) lung compliance was measured using invasive plethysmography and the forced oscillation 
technique (n = 5–8). Statistical differences were determined with 1-way ANOVA followed by Bonferroni’s posttest. *P < 0.05, **P < 0.01, and ****P < 0.0001 
compared with PBS-challenged WT or Fbln1c–/– controls. †P < 0.05, and ††P < 0.01 compared with bleomycin-challenged WT controls. NS, not significant.
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administered versus secreted. Thus, we measured Tgfb mRNA levels. Tgfb mRNA (Figure 5A) and LTBP1 
(Figure 5B) levels were increased in lung fibroblasts from both WT and Fbln1c–/– mice after stimulation. 
Thus, the levels of  Tgfb mRNA and LTBP1 were again unchanged in fibroblasts. Downstream p-Smad3 
protein levels were also increased in WT but again not in Fbln1c–/– fibroblasts after stimulation (Figure 5C).
TGF-β–stimulated fibroblasts from WT mice developed into myofibroblasts, as indicated by the presence 
of  α–smooth muscle actin (α-SMA), but this was significantly reduced in Fbln1c–/– mice (Figure 5D). TGF-β–
stimulated fibroblasts from WT mice had significantly increased Col1a1 mRNA (Figure 5E) and protein (Fig-
ure 5F) levels, but these were reduced and completely inhibited, respectively, in Fbln1c–/– fibroblasts.
To further explore the role of  Fbln1c in the TGF-β signaling pathway, we isolated primary fibroblasts 
from WT mouse lungs and treated them with BALF (20 μL per mouse from 6 mice pooled to a total of  120 
μL) from WT or Fbln1c–/– mice 28 days after bleomycin challenge or from controls, for 24 and 48 hours. 
However, fibroblasts from Fbln1c–/– but not WT mice were detached and dead at these time points. We 
therefore isolated fibroblasts at an earlier time point (6 hours) and lysates were collected. Smad2, -3, and 
-4 gene expression were largely unaltered in fibroblasts cultured with BALF from WT and Fbln1c–/– mice 
(Supplemental Figure 5, D–F). Col1a1 protein levels were also not changed in fibroblasts incubated with 
BALF from bleomycin-challenged compared to control WT mice. However, Col1a1 and p-Smad3 proteins 
were reduced in cells treated with BALF from Fbln1c–/– compared with WT mice (Figure 5, G and H).
Figure 3. Bleomycin challenge in Fbln1c–/– mice does not increase the levels of ECM proteins around the small airway or in whole lung tissue. A single 
bleomycin challenge was used to induce pulmonary fibrosis in WT and Fbln1c–/– mice that were assessed 28 days later. Controls received PBS. (A) Fibronec-
tin (Fn), (B) tenascin-C (Tnc), and (C) periostin (Postn) deposition in the basement membrane around small airways was assessed using immunohisto-
chemistry and stained areas quantified with normalization to the Pbm (n = 24–40 airways from n = 4–8 mice per group). (D) Fn, (E) Tnc, and (F) Postn 
mRNA levels in lungs were determined using qRT-PCR (n = 6–8). (G) Fn, Tnc (variants 1 and 2), and Postn protein levels in whole lung tissues were assessed 
using immunoblot (top), and fold change was quantified using densitometry with normalization to β-actin (bottom, n = 5–8). Statistical differences were 
determined with 1-way ANOVA followed by Bonferroni’s posttest. *P < 0.05, and **P < 0.01 compared with PBS-challenged WT controls. †P < 0.05, ††P < 
0.01, and ††††P < 0.0001 compared with bleomycin-challenged WT controls.
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Fbln1 colocalized with LTBP1 in lungs from patients with IPF. We show that Fbln1c binds to LTBP1 (Figure 
4E) to regulate TGF-β activation (Figure 4B) in mouse lungs. To further support this binding relationship in 
humans, we stained lung sections from patients with IPF and controls with Fbln1 and LTBP1 and assessed 
their colocalization. We detected Fbln1 here because of  lack of  a specific antibody to distinguish human 
Fbln1c by immunofluorescence. Fbln1 and LTBP1 protein colocalized in lung sections from patients with 
IPF but not controls without IPF (Figure 6).
Discussion
Aberrant deposition of ECM proteins and fibrosis have severe pathological consequences in many diseases, 
including in the respiratory tract, but no effective treatments currently exist. Here we identify a critical role 
for the ECM protein Fbln1c in regulating airway and lung remodeling during the pathogenesis of pulmonary 
fibrosis. For the first time to our knowledge, we showed specific increases in Fbln1c protein levels in the lungs 
of patients with IPF. Increased collagen and Fbln1c deposition were also observed around the airways and in 
the lung tissues in experimental bleomycin-induced pulmonary fibrosis. Genetic inhibition of Fbln1c prevented 
increases in bleomycin-induced collagen around the airways and in the lungs, inhibited MMP expression, and 
also protected against the impairment of lung function. Fbln1c also bound to Fn and Tnc, and these ECM pro-
teins and Postn were reduced with genetic inhibition. We discovered a potentially novel profibrotic mechanism 
whereby Fbln1c bound to LTBP1 to induce TGF-β activation of the downstream Smad3 pathway and collagen 
deposition, as well as the conversion of fibroblasts to myofibroblasts (Figure 7). We validated these experimental 
links by showing that Fbln1c colocalized with LTBP1 in the lung tissues of patients with IPF.
Several experimental models are available to examine lung fibrosis, all of  which have limitations. We 
employed the widely used bleomycin-induced mouse model of  pulmonary fibrosis to show that Fbln1c is 
increased around the airways and lungs. The concern with this model is that the bleomycin-induced fibrosis 
is partially reversible, unlike human lung fibrosis (26). However, it does develop histological alterations sim-
Figure 4. Fbln1c binds with LTBP1 to induce TGF-β activation. A single bleomycin challenge was used to induce pulmonary fibrosis in WT and Fbln1c–/– 
mice that were assessed 28 days later. Controls received PBS. TGF-β (A) mRNA and (B) active protein levels in whole lung tissues measured using qRT-PCR 
and ELISA (n = 4–8). (C) LTBP1 levels in lungs measured using immunoblot (left) and fold change quantification using densitometry with normalization to 
β-actin (right, n = 5–8). (D) p-Smad3 protein levels in lungs measured using immunoblot (left) and fold change quantified using densitometry with normal-
ization to vinculin (right, n = 5–8). (E) Immunoprecipitation (IP) of Fbln1c protein from whole lung tissues and detection of Fbln1c and LTBP1 binding using 
immunoblot (IB). IB analysis of lung tissues before (input) and after IP. Statistical differences were determined with 1-way ANOVA followed by Bonferroni’s 
posttest. *P < 0.05, and **P < 0.01 compared with PBS-challenged WT controls. †P < 0.05 compared with bleomycin-challenged WT controls.
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ilar to those observed in patients with IPF, and the use of  this model and analysis of  transgenic mice have 
greatly advanced our understanding of  the disease (26).
Through its interaction with multiple ECM proteins, Fbln1c was revealed to play a major role in 
directing ECM deposition in pulmonary fibrosis. Fbln1c–/– mice were completely protected against 
collagen deposition around the small airways and in whole lung tissues. Type I collagen is the most 
abundant ECM protein in the lung that constitutes the majority of  the matrix structure. Collagen pro-
duction can be regulated by fibroblast activation, inflammation, alterations in the balance of  enzymes 
that cleave and promote fiber assembly, and cross-linking and stability of  the ECM. Fbln1 is known to 
bind many other ECM proteins to stabilize the structure (27).
MMPs, particularly MMP1, -8, and -13, are prevalent proteases that degrade ECM proteins in the 
lung. MMP1 (protein) and MMP3 (protein and mRNA) levels are increased in the lungs of  patients with 
IPF, and Mmp3–/– mice are protected against bleomcyin-induced lung fibrosis (28). MMP8 protein levels 
Figure 5. Fbln1c binds to LTBP1 to activate TGF-β and induce fibroblast activation and collagen deposition. A single bleomycin challenge was used to 
induce pulmonary fibrosis in WT and Fbln1c–/– mice that were assessed 28 days later. Controls received PBS. (A) Tgfb mRNA levels in lungs were measured 
using qRT-PCR (n = 6). (B) LTBP1 levels in whole lung tissues were measured using immunoblot (left), and fold change was quantified using densitometry 
with normalization to β-actin (right, n = 6). Primary lung fibroblasts were isolated from whole lung tissues of naive WT and Fbln1c–/– mice and stimulated 
with TGF-β or control medium. (C) p-Smad3 protein levels in fibroblast lysates were measured using immunoblot (left), and fold change was quantified 
using densitometry with normalization to vinculin (right, n = 6). (D) Fibroblasts were stained with β-actin, and myofibroblasts were stained with α-SMA 
(left), and the percentage of myofibroblasts as a percentage of total fibroblasts was determined (right; scale bar: 500 μm; n = 6). (E) Col1a1 mRNA levels in 
fibroblast lysates were measured using qRT-PCR (n = 6). (F) Col1a1 protein levels in fibroblast lysates were measured using immunoblot, and fold change 
was quantified using densitometry with normalization to β-actin (right, n = 6). Primary mouse lung fibroblasts from WT mice were incubated with bron-
choalveolar lavage fluid (BALF, 20 μL each mouse, 120 μL total) from WT and Fbln1c–/– mice after 28 days of bleomycin challenge and PBS controls for 6 
hours. (G) Col1a1 and p-Smad3 protein in fibroblast lysates were measured using immunoblot, and (H) fold change was quantified using densitometry with 
normalization to vinculin (right, n = 6). Statistical differences were determined with 1-way ANOVA followed by Bonferroni’s posttest. *P < 0.05, **P < 0.01, 
***P < 0.001, and ****P < 0.0001 compared with WT fibroblast controls. †P < 0.05, and ††P < 0.01 compared with TGF-β–stimulated WT fibroblast controls.
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are also increased in the BALF from patients with IPF and in the lungs of  mice with bleomcyin-induced 
pulmonary fibrosis (29). We also found that MMPs were significantly increased in WT mouse lungs after 
bleomycin challenge. MMP activity is counterbalanced by the inhibitory activity of  TIMPs (30); according-
ly, we showed Timp1 mRNA expression was also increased in WT mouse lungs after bleomcyin challenge. 
Notably, the aberrant levels of  MMPs and Timp1 were not observed in Fbln1c–/– mice, identifying a poten-
tial role for Fbln1c in regulating MMP/TIMP activity in pulmonary fibrosis. MMPs are known to be able 
to limit the extent of  fibrosis and may be induced to control remodeling. Thus, in the absence of  Fibln1c 
and fibrosis, MMP responses are not needed. It remains unknown how Fbln1c regulates MMPs and TIMPs 
and whether the effects are direct or indirect, which requires further study.
Few studies have examined alterations in lung function in the bleomycin model, but we demon-
strated the impairment of  tissue damping, tissue elastance, and lung compliance, which are relevant 
to IPF physiology (31). Tissue damping is a measure of  whole lung tissue resistance, while tissue 
elastance and compliance indicate the level of  lung stiffness (32). Our lung function study results 
demonstrate that the lungs of  bleomycin-challenged WT mice stiffen because of  fibrosis, as occurs 
in patients with IPF (33, 34). However, these lung function changes do not develop in the absence 
of  Fbln1c, indicating its critical role in pulmonary fibrosis. Deletion of  total Fbln1 in mice results in 
perinatal lethality, but Fbln1c–/– mice develop a normal phenotype (1). Thus, therapeutically targeting 
Fbln1c, rather than total Fbln1, may limit adverse effects resulting from the total disruption of  Fbln1’s 
role in tissue homeostasis.
Other ECM proteins are also involved in the pathogenesis of  IPF. Lung fibroblasts from patients with 
IPF secrete more Fn and have the capacity to increase Tnc synthesis compared with those from healthy 
controls (35). We showed that Fn and Tnc deposition increased around small airways after bleomycin 
challenge of  WT mice and that Fbln1c was necessary for these increases. Furthermore, Fn, Tnc, and Postn 
protein levels in whole lung tissues were reduced in bleomycin-challenged Fbln1c–/– mice compared with 
WT controls. The ECM proteins Fn and Tnc were selected because of  their known interactions with Fbln1 
(1), while Postn was chosen for its indirect binding to Fbln1 and its effects on collagen deposition (36). It is 
likely that other ECM proteins are involved in the regulation of  matrix deposition. For example, versican 
affects the early stage of  repair processes in IPF (37); however, its protein levels were not changed in lungs 
between WT and Fbln1c–/– mice (data not shown). The protein levels of  elastin are increased in fibrotic 
lung tissue in patients with IPF (38), and many other ECM proteins may also be involved (39). However, a 
complete characterization of  the complex interactions that contribute to the generation of  aberrant ECM 
deposition is beyond the scope of  a single study. Levels of  ECM proteins may also be affected by changes 
in other factors that control their transcription, such as microRNAs, which have also been shown to be 
dysregulated in IPF (2), and other chronic fibrosis–associated diseases (40).
Figure 6. Fbln1 and LTBP1 colocalize in IPF patient lungs. Lung sections were obtained from patients with IPF and con-
trols. Fbln1 (shown in red) and LTBP1 (shown in green) were stained using immunofluorescence, and nuclei were stained 
with DAPI (shown in blue). Scale bar: 50 μm.
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TGF-β is the archetypal profibrotic cytokine that is increased in IPF lungs (18) and promotes cell prolifera-
tion and remodeling processes. It is initially synthesized in a precursor form, dimerizes, and is cleaved by the pro-
tease furin (41). This results in the release of a small latent complex, which attaches to LTBP1 (41). Anchoring 
of this complex to the ECM occurs through interactions of ECM proteins with the EGF-like repeat domains on 
the N-terminus of the LTBP1 protein (42). From the anchored complex, activated TGF-β is released via several 
mechanisms, which induce downstream signaling pathways (43). Fbln1c contains EGF-like binding regions 
(16), which in itself  indicates a potential role in TGF-β activation. We showed that Fbln1 and LTBP1 colocal-
ized in lungs from patients with IPF. Interestingly, monkey Fbln1c was reported to interact with heparin-binding 
EGF-like modules (44). Other studies show that Fbln5 binds to the N-terminal EGF-like domain of LTBP2 (45). 
We showed that Fbln1c binds with LTBP1 and regulates TGF-β activation. TGF-β signaling via Smad effectors 
is well known to be involved in cell growth and proliferation and ECM deposition in fibroblasts (43). Previous 
Figure 7. Proposed role of Fbln1c in pulmonary fibrosis: Fbln1c binds to LTBP1 to activate TGF-β and induce myofi-
broblast proliferation and collagen production. TGF-β precursors dimerize and are cleaved by the endopeptidase furin 
to form small latent complexes. LTBP1 binds to small latent complexes, and the entire combination is secreted into the 
extracellular space. Fbln1c protein binds to LTBP1 likely via EGF-like domains on both, causing the release of activated 
TGF-β. Fbln1c-induced, activated TGF-β binds to its receptor on the surface of fibroblasts to stimulate the development 
and proliferation of myofibroblasts through the activity of p-Smad3, causing increased collagen production and pulmo-
nary fibrosis. Fbln1c also associates with Fn, Tnc, and Postn to stabilize the resulting collagen structure.
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studies demonstrated reduced Smad3 mRNA and protein levels in the lungs of mice with bleomycin-induced 
pulmonary fibrosis (46). We corroborated these decreases in Smad3 mRNA expression but in contrast found 
increased p-Smad3 protein levels in WT mouse lungs after bleomycin challenge and fibroblasts after TGF-β 
stimulation. However, the altered p-Smad3 levels did not occur in the absence of Fbln1c. This demonstrates roles 
for Fbln1c in controlling TGF-β activation and signaling pathways that lead to pulmonary fibrosis.
We found that lung fibroblasts from WT mice incubated with BALF from Fbln1c–/– mice for 6 hours 
reduce p-Smad3 and collagen proteins compared with those cells received in BALF from WT mice. Longer 
incubations (24 and 48 hours) with BALF from Fbln1c–/– mice resulted in fibroblasts detached from plates. 
The exact reason remains unclear, although the fibroblasts’ detachment may be due to decreased collagen. 
Many studies have shown that collagen is essential to assist fibroblasts’ attachment (47). LTBP1 is secreted 
into the airway fluid; however, the lack of  active TGF-β in the BALF of  Fbln1c–/– mice reduced the collagen 
levels in fibroblasts. This further supports our findings that Fbln1c regulates TGF-β activation.
Integrins are cell membrane receptors that facilitate ECM protein binding and adhesion. They are also 
involved in TGF-β activation; Henderson et al. showed that inhibition of  the expression of  the αv subunit 
reduced TGF-β levels in fibroblasts and protected against fibrosis in an experimental animal model of  liver 
fibrosis (47, 48). This study also suggested that αvβ1 integrin is a major regulator of  TGF-β activation. There 
are several therapeutic compounds that target the αv integrin that are currently in clinical trials to reduce 
fibrosis (48). Previous studies showed that Fbln1c might be mediated through αvβ1 integrin signaling; how-
ever, the relationship between Fbln1c and integrins in lung fibrosis remains unknown.
ECM proteins are deposited in excess in many pulmonary diseases, and Fbln1, in particular Fbln1c, 
is involved in regulating remodeling and fibrosis in lungs (1, 20). We have shown that genetic inhibition of  
Fbln1c in mice substantially reduced pulmonary remodeling and fibrosis in cigarette smoke–induced COPD 
and house dust mite–induced asthma (1, 20). Our previous studies also showed that specific inhibition of  
Fbln1c gene expression with siRNA also similarly reduced remodeling features. Thus, targeting the Fbln1c 
gene, for example with antisense oligonucleotides, may be a therapeutic option to reduce fibrosis in lungs. We 
show that Fbln1c regulates fibrosis by binding with LTBP1 to control TGF-β activation. Inhibiting Fbln1c 
binding to LTBP1 binding is another potential therapeutic option to reduce active TGF-β and lung fibrosis.
We showed that TGF-β–induced conversion of  fibroblasts to myofibroblasts is substantially reduced 
in the absence of  Fbln1c. Fibroblasts/myofibroblasts are the major cellular source of  collagen (49). These 
cells have altered autophagic pathways in patients with IPF (50), produce more Fbln1 (18), and are import-
ant in maintaining a pathological profibrotic phenotype, particularly in a collagen-rich environment (51).
We previously showed that Fbln1, but not specifically Fbln1c, protein levels were increased in the serum/
plasma and lung tissue of patients with IPF (18). Fbln1, like other ECM proteins, is constantly being produced 
and degraded. This is partly because of the activity of specific proteases, such as MMP13 (52). Peptide products 
resulting from ECM degradation are not necessarily inert and may have immunomodulatory effects. Peptides 
from ECM degradation induce the proliferation, migration, and MMP production and ECM deposition of air-
way smooth muscle (ASM) cells and myofibroblasts (53, 54). Protein fragments generated by MMP activity are 
increased in the serum of patients with IPF compared with healthy controls and are associated with disease pro-
gression (55). Other studies showed that Fbln1c peptides increase the attachment of ASM cells and fibroblasts 
(19). Also, Fbln1c peptide stimulates Fbln1 deposition in fibroblasts from patients with IPF and augments the 
production of Fn and perlecan (19). Thus, the increase in Fbln1 and Fbln1c may provide substrates for MMPs to 
generate peptide fragments that contribute to the development of remodeling and disease in IPF.
Considering previous and our new data together, Fbln1c associates with Fn, Tnc, and Postn to stabi-
lize the resulting collagen structure. It also induces increased MMP activity that drives the production of  
ECM fragments, further stimulating fibroblast activity and perpetuating fibrosis. Collectively these events 
promote the deposition of  ECM and stabilize exaggerated ECM formation around the airways and in lung 
tissues in IPF. We propose (Figure 7) that excess Fbln1c is induced during remodeling events and promotes 
the development of  fibrosis. TGF-β precursors dimerize and are cleaved by the endopeptidase furin to form 
small latent complexes (41). LTBP1 binds to these complexes and the entire combination is secreted into 
the extracellular space (42). Fbln1c protein binds to LTBP1 via EGF-like domains, causing the release of  
activated TGF-β. It also regulates fibroblasts’ activation and the TGF-β signaling pathway to induce myofi-
broblast development and collagen production. This study provides our fundamental knowledge of  fibrosis 
and further increases understanding of  mechanism of  TGF-β activation. Thus, Fbln1c may be a novel 
therapeutic target for suppressing fibrosis in IPF and potentially other fibrotic diseases.
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Methods
Human lung tissue. Lung tissue for Fbln1c immunohistochemistry staining (Figure 1A) was obtained from 
patients with IPF (n = 7). All patients with IPF had end-stage disease and underwent lung transplantation 
(Table 1). The non-IPF control group (n = 8) consisted of  4 donor lungs that were not used in transplanta-
tion and lung tissues from 4 subjects with normal lung function (FEV1 > 80% and FEV1/FVC ratio > 0.7) 
who had lung tissue removed for thoracic malignancies. Human tissues for colocalization immunohisto-
chemical staining (Figure 6) were procured from nontransplantable donors and patients with IPF undergo-
ing lung transplantation or lung resection.
Immunohistochemistry and remodeling. Human and mouse lung longitudinal sections on slides were incu-
bated with citrate buffer (10 mM sodium citrate, 0.05% Tween-20, pH 6) for antigen retrieval after depa-
raffinization. Lung sections were blocked with casein (MilliporeSigma) at room temperature for 1 hour. 
Slides were incubated with monoclonal anti-Fbln1c antibody (mAB5D12, 1:50), which was produced as 
previously described (16), and Fbln1 (1:50, Abcam), Col1a1 (1:100, Abcam), Tnc (1:50, Santa Cruz Bio-
technology), Fn (1:100, MilliporeSigma), and Postn (1:100, Abcam) antibodies, at 4°C overnight, followed 
by antirabbit secondary antibody (R&D Systems) at room temperature for 1 hour. Diaminobenzidine 
(DAKO) was applied and hematoxylin was used to counterstain the sections. Lung remodeling analyses 
were assessed as previously described (1, 18).
Mice and experimental model. Female 6- to 8-week-old WT C57BL/6J or Fbln1c–/– mice were housed in 
specific pathogen–free conditions. Fbln1c–/– mice were generated as previously described (1). Experimental 
pulmonary fibrosis was induced by administration of  a single dose of  bleomycin sulfate (0.05 U/mouse, 
MP Biomedical) as described previously (21–23). Controls received an equal volume of  sterile PBS. Tissues 
were collected 7, 14, 21, and 28 days after bleomycin challenge.
Lung remodeling. Formalin-fixed, paraffin-embedded mouse lung sections were deparaffinized with 
xylene and a graded ethanol series (56). Collagen was stained with Verhoeff-Van Gieson stain (Australian 
Biostain). Fbln1, Fbln1c, Fn, Tnc, and Postn were stained by immunofluorescence or immunohistochem-
istry. Photomicrographs were taken with an Axio Imager M2 microscope (Zeiss) and images evaluated 
with ImageJ (version 1.47, NIH) as previously described (23, 57, 58). Briefly, at least 6 airways per mouse 
were selected while blinded to condition from 4–8 animals in each group, and images were captured with 
an Aperio AT2 (Leica Biosystems). Mouse small airways were defined as those having the Pbm less than 1 
mm (59). The Pbm, the inner collagen area (Ai) and the outer collagen area (Ao) were manually measured 
using ImageJ. The collagen area (Wct) was calculated (Wct = Ao – Ai) and normalized to the Pbm. For 
quantification in whole lungs, Fbln1c area was normalized to total area as previously described (18).
Hydroxyproline. Hydroxyproline content in mouse whole lung tissues were assessed as a measure of  
lung collagen levels. Content was measured colorimetrically as previously described (1, 60, 61).
Soluble collagen assay. Soluble collagen was determined using Sircol Collagen Assay kits (S1000, Biocol-
or) according to the manufacturer’s instructions with modifications as previously described (1).
Protein extraction and immunoblotting. Mouse lung tissues were snap-frozen and thawed before being 
homogenized in radioimmunoprecipitation assay buffer (MilliporeSigma) supplemented with PhosSTOP 
phosphatase inhibitor and complete protease inhibitor cocktails (Roche) and centrifuged (8000 g, 10 min-
utes, 4°C) as previously described (58, 62). Proteins were collected for immunoblot assay or ELISA. Protein 
concentrations were determined using a BCA protein assay kit (Pierce Biotechnology).
Proteins were separated by SDS-PAGE using Mini-PROTEAN TGX Stain-Free gels (Bio-Rad) and 
transferred to polyvinylidene fluoride membranes (MilliporeSigma) (63). Proteins of  interest were detected 
using Fbln1 (1:2000, ab175204, Abcam), the Fbln1c antibody described above, Col1a1 (1:5000, ab34170, 
Abcam), Tnc (1:500, sc20932, Santa Cruz Biotechnology), Fn (1:4000, F3648, MilliporeSigma), Postn 
(1:4000, ab14041, Abcam), LTBP1 (1:1000, abs504, MilliporeSigma), p-Smad3 (1:2000, ab52903, Abcam), 
vinculin (1:10,000, ab129002, Abcam), and β-actin (1:10,000, ab8227, Abcam) antibodies at 4°C overnight. 
Blots were incubated with antimouse (ab97023, Abcam) or antirabbit horseradish peroxidase–conjugated 
secondary antibody (HAF008, R&D systems) at room temperature for 2 hours. Images of  immunoblots 
were captured with a ChemiDoc MP System (Bio-Rad). Some blots were cut based on the protein molecu-
lar weight. ImageJ was used for densitometry analysis as described previously (1, 64).
Immunofluorescence. Mouse and human lungs were formalin fixed and paraffin embedded (1, 56, 
65, 66). Sections were cut to 4-μm thickness. Slides were deparaffinized and incubated with Tris buffer 
(10 mM Tris base, 0.5% Tween 20, pH 9) at 100°C for antigen retrieval and blocked with casein (Milli-
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poreSigma) at room temperature for 2 hours. Slides were stained with the Fbln1c antibody (1:20) that 
was conjugated with FITC using a kit (ab102884, Abcam) at 4°C overnight. Nuclei were counterstained 
with Hoechst (1:200, MilliporeSigma) at room temperature for 5 minutes (65). Images were taken using 
an Axio Imager M2 microscope.
Mouse primary fibroblasts were fixed with 3% paraformaldehyde in PBS (pH 7.4) at room temperature 
for 10 minutes, permeabilized with 0.2% Triton X-100, blocked with casein at room temperature for 1 hour, 
and incubated with anti–mouse β-actin antibody (1:1000, ab8227, Abcam) at room temperature for 1 hour. 
After 3 PBS-Tween washes, cells were incubated with FITC-conjugated antimouse secondary antibody 
(1:1000, ab6717, Abcam) at room temperature for 1 hour. Cells were incubated with a Cy3-conjugated 
anti–mouse α-SMA antibody (1:200, c6198, MilliporeSigma) at room temperature for 2 hours, and nuclei 
were counterstained with Hoechst. Per section, 10 random images were visualized using an Axio Imager 
M2 microscope and analyzed using imaging software (Zen, Zeiss). The percentage of  myofibroblasts was 
calculated as the percentage of  α-SMA–positive cells in the total cell number (β-actin–positive cells).
Human lung sections were deparaffinized and incubated with citrate for antigen retrieval at 100°C for 
15 minutes. Slides were incubated overnight with anti-Fbln1 (1:50, ab211536, Abcam) in PBS with 1% 
BSA at 4°C overnight, followed by antimouse Alexa Fluor 647–conjugated secondary antibody (1:100, 
A-31571, Thermo Fisher Scientific) at room temperature for 2 hours. After slides were washed with PBS, 
they were incubated with anti-LTBP1 (1:100, ab78294, Abcam) at room temperature for 2 hours, followed 
by antirabbit Alexa Fluor 555–conjugated secondary antibody (1:100, A-31572 Thermo Fisher Scientific). 
Nuclei were counterstained with DAPI (10236276001, MilliporeSigma). Fluorescence signals were exam-
ined using a Leica TCS SP8 confocal microscope (Leica Microsystems).
ELISA. Cytokines in lung tissues were assessed by ELISA as previously described (58, 67). The con-
centrations of  TGF-β were determined using capture and detection antibodies (555052 and 555053, BD 
Pharmingen), according to the manufacturer’s instructions. The levels of  target proteins in lungs were nor-
malized to total lung protein.
Immunoprecipitation. Fbln1c proteins were immunoprecipitated from lung homogenates from WT and 
Fbln1c–/– mice using a Dynabead protein A immunoprecipitation kit (10006D, Life Technologies) according to 
the manufacturer’s instructions. Briefly, Fbln1c antibody (10 μg) was added to lung homogenates and incubated 
with rotation at 4°C overnight. Dynabeads (1.5 mg), superparamagnetic particles that have specific affinity to 
bind to antibody, were added into the protein and antibody complex and incubated with rotation at 4°C for 1 
hour. The bead–antibody and protein complex were separated from the solution by magnet. Nonbinding pro-
teins were washed off 3 times with PBS, and target proteins were collected by adding elution buffer (from kit) 
and Laemmli sample buffer (1610747, Bio-Rad) containing 2-mercaptoethanol (1610710, Bio-Rad) and heated 
at 90°C for 10 minutes. SDS-PAGE was used to detect the target Fbln1c protein and its binding partners.
RNA extraction and qRT-PCR. Total RNA was extracted using TRIzol (Invitrogen) and reverse-tran-
scribed using Bioscript (Bioline) and random hexamer primers (Invitrogen). Quantitative real-time PCR 
(qRT-PCR) was performed using SYBR reagents and a Viia 7 real-time PCR system (Life Technologies). 
Primers are listed in Table 2. mRNA levels were normalized to those of  the housekeeping gene hypoxan-
thine-guanine phosphoribosyltransferase and expressed as relative abundance in the control group (67, 68).
SHG microscopy. Formalin-fixed, paraffin-embedded mouse lung sections were cut to 10-μm thickness. 
Sections were deparaffinized with xylene and a graded ethanol series, then dehydrated and coverslipped for 
SHG using a Leica SP5 multiphoton confocal system with an excitation wavelength of  810 nm throughout. 
FSHG and BSHG signals were obtained, and image analysis was performed using Fiji with images imported 
from LAS AF software as previously described (24, 69). In brief, a quarter-wave plate (CVI Laser Optics) 
was used to produce circularly polarized light to detect maximum collagen content. The incident laser 
power was adjusted to the same level (25 mW) throughout the experiment, and SHG signals were detected 
with a 405/10-nm band-pass filter. Then, 10 random pictures without large airways and blood vessels were 
selected. The pixel area (the number of  pixels with intensity above threshold) and total signal intensity 
(total intensity for all pixels with intensity above threshold) were determined and the average values calcu-
lated for every image in the stack. The process was repeated for both FSHG- and BSHG-propagated signals. 
The ratio of  FSHG/BSHG signal was then calculated for area measurements.
Lung function. Mice were anesthetized (50 μL/10 g, intraperitoneally) with a mix of  xylazine (2 mg/
mL, Troy Laboratories) and ketamine (40 mg/mL, Parnell). Mice were tracheotomized and a cannula 
was inserted into the trachea. Animals were ventilated with a tidal volume of  8 mL/kg at a rate of  450 
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breaths/min, with increased airway pressure from 2–30 cmH2O into mouse lungs to measure baseline 
lung function parameters, including tissue damping, tissue elastance, and lung compliance using inva-
sive plethysmography with the forced oscillation technique and Flexivent apparatus (Scireq) as previ-
ously described (1, 56, 58, 70).
Lung fibroblast isolation and culture. Lungs were excised from 6-week-old WT or Fbln1c–/– mice, and pri-
mary fibroblasts were isolated as described previously (71, 72). The cells were cultured in Dulbecco’s mod-
ified Eagle medium (DMEM, D5671, MilliporeSigma) containing 10% fetal bovine serum (Bovogen), 25 
mmol HEPES buffer, 100 U/mL penicillin, and 100 μg/mL streptomycin (37°C, 5% CO2) and used from 
passages 3–7. Primary fibroblasts were seeded at 5000 cells/cm2 and incubated overnight to allow cells to 
form a monolayer. Fibroblasts were stimulated with recombinant TGF-β protein (5 ng/mL, R&D Systems) 
supplemented with 0.5% FCS in DMEM or with medium only (control) for 48 hours. Cell lysates were 
collected for RNA and protein extraction, and myofibroblasts were analyzed using immunofluorescence.
Lung fibroblasts were isolated from WT mice and cultured in 6-well plates with BALF (20 L each 
mouse, 6 mice per group, 120 L in total in 1 mL DMEM with 10% FCS) from bleomycin-challenged or 
control WT and Fbln1c–/– mice for 6, 24, and 48 hours. Cell lysates were collected for protein analysis.
Statistics. Results are presented as mean ± SEM from 7–8 human samples or 6–8 mice in duplicate or 
triplicate experiments. Statistical significance of  data between 2 groups was determined using a 2-tailed 
Student’s t test and of  data from more than 2 groups was analyzed using 1-way ANOVA with Bonferroni’s 
posttest and GraphPad Prism software (version 6). Statistical differences were accepted at P < 0.05.
Study approval. All procedures were approved by the University of  Newcastle or the University Medical 
Centre Groningen Human and Animal Ethics Committees. The human subjects and/or their guardians pro-
vided informed consent before participation in this study.
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